Gigantol inhibits the proliferation, migration and invasion of osteosarcoma cells by NF-κB/PRL-3 pathway
10.3872/j.issn.1007-385x.2019.10.007
- VernacularTitle:石斛酚通过NF-κB/PRL-3通路抑制骨肉瘤细胞增殖、迁移和侵袭
- Author:
FAN Zhaoyang
;
XIAN Wenfeng
;
LIU Yongxi
;
ZHANG Chao
- Publication Type:Journal Article
- Keywords:
gigantol;
osteosarcoma;
U20S cell;
proliferation;
invasion;
migration;
NF-κB;
PRL-3
- From:
Chinese Journal of Cancer Biotherapy
2019;26(10):1095-1100
- CountryChina
- Language:Chinese
-
Abstract:
To study the inhibitory effect of gigantol on proliferation, migration and invasion of human osteosarcoma U20S cells and to explore the mechanism. Methods: After being treated with different concentrations (10, 25, 50, 75, 100, 150 µmol/L) of gigantol for 24 and 48 h, the proliferation of U20S cells was detected by CCK-8 assay. Transwell assay was used to detect the effects of 25 µmol/L and 50 µmol/L gigantol on the migration and invasion abilities of U20S cells. The lipopolysaccharide (LPS) was used to induce inflammatory reaction in U20S cells before gigantol treatment; qPCR and WB were used to detect the mRNA and protein expressions of NF-κB (p65), TNF-α, IL-6 and PRL-3, respectively. Results: Different concentrations of gigantol could all inhibit the proliferation of sarcoma U20S cells at different time (P<0.05 or P<0.01). The 25 µmol/L and 50 µmol/L of gigantol could significantly inhibit the migration and invasion of osteosarcoma U20S cells (all P<0.01); at the same time, it could inhibit the protein expressions of NF-κB, TNF-α, IL-6 and PRL-3 (P<0.05 or P<0.01). After LPS induction, the mRNA and protein expressions of NF-κB, TNF-α, IL-6 and PRL-3 in U20S cells were significantly increased (all P<0.01); however, the consequent treatment with gigantol (25 and 50 µmol/L) reversed the effects of LPS on U20S cells obviously (P<0.05 or P<0.01). Conclusion: Gigantol can inhibit the proliferation, migration and invasion of osteosarcoma U20S cells, and its mechanism may be related to the regulation of NF-κB/PRL-3 signaling pathway.
- Full text:20191007.pdf
